Recombinant Human DNAM-1/CD226 Fc Avi-tag Protein, CF

When Recombinant Human CD155/PVR Fc Chimera (Catalog # 9174-CD) is immobilized at 2 μg/mL, Recombinant Human DNAM-1/CD226 Fc Chimera Avi-tag (Catalog # AVI666) binds with an ED50 of 0.07-0.42 μg/mL.

2 μg/lane of Recombinant Human DNAM-1/CD266 Fc Chimera Avi-tag (Catalog # AVI666) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 83-95 kDa and 170-190 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human DNAM-1/CD226 Fc Avi-tag Protein, CF Summary

• Additional Information: Biotinylated
• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human CD155/PVR Fc Chimera (Catalog # 9174-CD) is immobilized at 2 μg/mL (100 μL/well), the concentration of Recombinant Human DNAM-1/CD226 Fc Chimera Avi-tag (Catalog # AVI666) that produces 50% of the optimal binding response is 0.07‑0.42 μg/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human DNAM-1/CD226 protein
  

  Human DNAM-1 (Glu19-Asn247) Accession # Q15762	HIEGRMD	Human IgG1 (Pro100-Lys330)	Avi-tag
  N-terminus			C-terminus

• Accession #: Q15762
• N-terminal Sequence: Glu19
• Structure / Form: Disulfide-linked homodimer, biotinylated via Avi-tag
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 55 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 83-95 kDa

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human DNAM-1/CD226 Fc Avi-tag Protein, CF

• CD226 antigenplatelet and T cell activation antigen 1
• CD226 molecule
• CD226
• DNAM1
• DNAM-1
• DNAM1adhesion glycoprotein
• DNAM-1DNAX accessory molecule-1
• DNAX accessory molecule 1
• PTA1
• T lineage-specific activation antigen 1 antigen
• TLiSA1

Background

DNAX accessory molecule-1 (DNAM-1), also known as CD226, is a 65 kDa type I transmembrane glycoprotein in the immunoglobulin superfamily (1). Mature human DNAM-1 contains a 236 amino acid (aa) extracellular domain (ECD) with two Ig-like C2-set domains and a 61 aa cytoplasmic region that contains motifs for binding PDZ domains and band 4.1 family proteins (1, 2). Within the ECD, human DNAM-1 shares 50% and 52% aa sequence identity with mouse and rat DNAM-1, respectively. DNAM-1 is expressed on multiple lymphoid and myeloid cells and interacts with CD155/PVR and Nectin-2/CD112 (3, 4). Ligation of DNAM-1 promotes the activation of NK cells, CD8⁺ T cells, and mast cells (2-6), dendritic cell maturation, megakaryocyte and activated platelet adhesion to vascular endothelial cells, and monocyte extravasation; it inhibits the forrmation of osteoclasts (7-10). Platelet-endothelium interactions mediated by DNAM-1 enable the metastasis of tumor cells to the lung (11). In activated, but not in resting NK, T, and mast cells, the cis association of DNAM-1 with CD18 contributes to the tyrosine and serine phosphorylation of DNAM-1 during activation (6, 9, 12-14).

1. Fuchs, A. and M. Colonna (2006) Semin. Cancer Biol. 16:359.
2. Shibuya, A. et al. (1996) Immunity 4:573.
3. Bottino, C. et al. (2003) J. Exp. Med. 198:557.
4. Tahara-Hanaoka, S. et al. (2004) Int. Immunol. 16:533.
5. Dardalhon, V. et al. (2005) J. Immunol. 175:1558.
6. Bachelet, I. et al. (2006) J. Biol. Chem. 281:27190.
7. Reymond, N. et al. (2004) J. Exp. Med. 199:1331.
8. Kakehi, S. et al. (2007) Mol. Cell. Biochem. 301:209.
9. Kojima, H. et al. (2003) J. Biol. Chem. 278:36748.
10. Tahara-Hanaoka, S. et al. (2006) Blood 107:1491.
11. Morimoto, K. et al. (2007) Oncogene July 16 epub.
12. Shibuya, K. et al. (1999) Immunity 11:615.
13. Shibuya, K. et al. (2003) J. Exp. Med. 198:1829.
14. Shibuya, A. et al. (1998) J. Immunol. 166:1671.

Bioinformatics

• Uniprot:
  • Q15762()